

Supplementary Table 2. Baseline characteristics of patients with digestive tumours at sNRP2 assays.

| | Digestive tumour patients n=30 | sNRP2 levels | | | | | |
|---|--------------------------------------|------------------------------|------------------------------|---------|--------------------------------|-------------------------------|---------|
| | | sNRP2 ^{Nor} n=19 | sNRP2 ^{Abn} n=11 | p-value | sNRP2 ^{Q0-Q3} n=23 | sNRP2 ^{Q3-Q4} n=7 | p-value |
| Women, n (%) | 16 (53) | 10 (53) | 6 (55) | 0.919 | 12 (52) | 4 (57) | 0.818 |
| Age in years, median (IQR Q1-Q3) | 69 (60-78) | 69 (63-80) | 69 (47-77) | 0.642 | 69 (60-76) | 76 (47-78) | 0.782 |
| Renal deficiency, n (%) | 5 (17) | 4 (21) | 1 (9) | 0.157 | 4 (17) | 1 (14) | 0.847 |
| Inflammatory syndrome, n (%) | 14 (47) | 7 (37) | 7 (64) | 0.110 | 9 (39) | 5 (71) | 0.134 |
| Time (months) from diagnosis to NRP2 assay, median (IQR Q1-Q3) | 13 (5-30) | 14 (5-31) | 9 (1-26) | 0.256 | 12 (5-31) | 15 (9-26) | 0.622 |
| Primary tumour site, colon-rectum vs other, n (%) | | | | 0.450 | | | 0.172 |
| Colorectal | 17 (57) | 12 (63) | 5 (45) | | 14 (61) | 3 (43) | |
| Pancreas- Biliary tract | 10 (33) | 6 (32) | 4 (36) | | 8 (35) | 2 (29) | |
| Stomach | 3 (10) | 1 (5) | 2 (18) | | 1 (4) | 2 (29) | |
| Number of metastatic sites, n (%) | | | | 0.161 | | | 0.428 |
| 0 | 13 (43) | 7 (37) | 6 (55) | | 10 (43) | 3 (43) | |
| 1 | 9 (30) | 8 (42) | 1 (9) | | 8 (35) | 1 (14) | |
| ≥2 | 8 (27) | 4 (21) | 4 (36) | | 5 (22) | 3 (43) | |
| Localisation of metastases, n (%) | | | | | | | |
| Liver | 10 (33) | 7 (37) | 3 (27) | 0.592 | 8 (35) | 2 (29) | 0.760 |
| Distant lymph nodes | 7 (23) | 6 (32) | 1 (9) | 0.160 | 6 (26) | 1 (14) | 0.518 |
| Peritoneum | 6 (20) | 2 (11) | 4 (36) | 0.088 | 3 (13) | 3 (43) | 0.084 |
| Lung | 3 (10) | 1 (5) | 2 (18) | 0.256 | 2 (9) | 1 (14) | 0.666 |
| Other | 2 (7) ^a | 1 (5) | 1 (9) | 0.181 | 1 (4) | 1 (14) | 0.356 |
| Prior locoregional treatment, n (%) | | | | | | | |
| Surgery of primary tumour | 20 (67) | 15 (79) | 5 (45) | 0.061 | 16 (70) | 4 (57) | 0.542 |
| Surgery of metastases | 5 (17) | 4 (21) | 1 (9) | 0.397 | 4 (17) | 1 (14) | 0.847 |
| Prior systemic chemotherapy, n (%) | 21 (70) | 12 (63) | 9 (82) | 0.283 | 15 (65) | 6 (86) | 0.05 |
| Concurrent proton pump inhibitors, n (%) | 16 (53) | 10 (53) | 6 (55) | 0.705 | 12 (52) | 4 (57) | 0.818 |
| sNRP2 in ng/mL, median (IQR Q1-Q3) | 1.8 (1.2-3.6) | 1.2 (1.0-1.7) | 3.6 (3.1-4.6) | <0.0001 | 1.3 (1.0-2.0) | 4.3 (3.6-8.1) | <0.0001 |

Legend: Nor, normal values; Abn, abnormal values; IQR, interquartile range; NRP2, neuropilin-2; sNRP2, soluble neuropilin-2

^a Ovary and rectum (n=1), adrenal gland (n=1).